Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy
- PMID: 34298972
- PMCID: PMC8306915
- DOI: 10.3390/ijms22147352
Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy
Abstract
Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited multiple cancer syndrome of neuroendocrine tissues. Tumors are caused by an inherited germinal heterozygote inactivating mutation of the MEN1 tumor suppressor gene, followed by a somatic loss of heterozygosity (LOH) of the MEN1 gene in target neuroendocrine cells, mainly at parathyroids, pancreas islets, and anterior pituitary. Over 1500 different germline and somatic mutations of the MEN1 gene have been identified, but the syndrome is completely missing a direct genotype-phenotype correlation, thus supporting the hypothesis that exogenous and endogenous factors, other than MEN1 specific mutation, are involved in MEN1 tumorigenesis and definition of individual clinical phenotype. Epigenetic factors, such as microRNAs (miRNAs), are strongly suspected to have a role in MEN1 tumor initiation and development. Recently, a direct autoregulatory network between miR-24, MEN1 mRNA, and menin was demonstrated in parathyroids and endocrine pancreas, showing a miR-24-induced silencing of menin expression that could have a key role in initiation of tumors in MEN1-target neuroendocrine cells. Here, we review the current knowledge on the post-transcriptional regulation of MEN1 and menin expression by miR-24, and its possible direct role in MEN1 syndrome, describing the possibility and the potential approaches to target and silence this miRNA, to permit the correct expression of the wild type menin, and thereby prevent the development of cancers in the target tissues.
Keywords: MEN1 gene; loss of heterozygosity (LOH); miR-24; microRNA (miRNAs); multiple endocrine neoplasia type 1 (MEN1).
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Multiple Endocrine Neoplasia Type 1: The Potential Role of microRNAs in the Management of the Syndrome.Int J Mol Sci. 2020 Oct 14;21(20):7592. doi: 10.3390/ijms21207592. Int J Mol Sci. 2020. PMID: 33066578 Free PMC article. Review.
-
Menin is required for optimal processing of the microRNA let-7a.J Biol Chem. 2014 Apr 4;289(14):9902-8. doi: 10.1074/jbc.M113.520692. Epub 2014 Feb 21. J Biol Chem. 2014. PMID: 24563463 Free PMC article.
-
Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients.Cancer Gene Ther. 2010 Nov;17(11):814-25. doi: 10.1038/cgt.2010.39. Epub 2010 Aug 13. Cancer Gene Ther. 2010. PMID: 20706287
-
An autoregulatory network between menin and pri-miR-24-1 is required for the processing of its specific modulator miR-24-1 in BON1 cells.Mol Biosyst. 2016 May 24;12(6):1922-8. doi: 10.1039/c6mb00118a. Mol Biosyst. 2016. PMID: 27098433
-
Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.Hum Mutat. 2008 Jan;29(1):22-32. doi: 10.1002/humu.20605. Hum Mutat. 2008. PMID: 17879353 Review.
Cited by
-
MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives.Cancers (Basel). 2022 Feb 10;14(4):876. doi: 10.3390/cancers14040876. Cancers (Basel). 2022. PMID: 35205624 Free PMC article. Review.
-
Conservation and Targets of miR-71: A Systematic Review and Meta-Analysis.Noncoding RNA. 2023 Jul 26;9(4):41. doi: 10.3390/ncrna9040041. Noncoding RNA. 2023. PMID: 37624033 Free PMC article. Review.
-
GONNMDA: A Ordered Message Passing GNN Approach for miRNA-Disease Association Prediction.Genes (Basel). 2025 Apr 1;16(4):425. doi: 10.3390/genes16040425. Genes (Basel). 2025. PMID: 40282386 Free PMC article.
-
Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.Int J Mol Sci. 2024 Jan 22;25(2):1331. doi: 10.3390/ijms25021331. Int J Mol Sci. 2024. PMID: 38279330 Free PMC article. Review.
-
[Plasma miRNA expression in patients with genetically confirmed multiple endocrine neoplasia type 1 syndrome and its phenocopies].Probl Endokrinol (Mosk). 2024 Jan 24;69(6):70-85. doi: 10.14341/probl13357. Probl Endokrinol (Mosk). 2024. PMID: 38311997 Free PMC article. Russian.
References
-
- Thakker R.V., Newey P.J., Walls G.V., Bilezikian J., Dralle H., Ebeling P.R., Melmed S., Sakurai A., Tonelli F., Brandi M.L. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1) J. Clin. Endocrinol. Metab. 2012;97:2990–3011. doi: 10.1210/jc.2012-1230. - DOI - PubMed
-
- Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., Debelenko L.V., Zhuang Z., Lubensky I.A., Liotta L.A., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–407. doi: 10.1126/science.276.5311.404. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical